Advertisement
Advertisement

KPTI

KPTI logo

Karyopharm Therapeutics Inc.

6.29
USD
Sponsored
+0.20
+3.27%
Feb 06, 16:00 UTC -5
Closed
exchange

After-Market

6.24

-0.05
-0.86%

KPTI Earnings Reports

Positive Surprise Ratio

KPTI beat 24 of 40 last estimates.

60%

Next Report

In 4 Days
Date of Next Report
Feb 12, 2026
Estimate for Q4 25 (Revenue/ EPS)
$36.17M
/
-$2.14
Implied change from Q3 25 (Revenue/ EPS)
-17.87%
/
-43.98%
Implied change from Q4 24 (Revenue/ EPS)
+18.44%
/
-40.56%

Karyopharm Therapeutics Inc. earnings per share and revenue

On Nov 03, 2025, KPTI reported earnings of -3.82 USD per share (EPS) for Q3 25, missing the estimate of -3.19 USD, resulting in a -19.63% surprise. Revenue reached 44.04 million, compared to an expected 42.04 million, with a 4.78% difference. The market reacted with a +4.66% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -2.14 USD, with revenue projected to reach 36.17 million USD, implying an decrease of -43.98% EPS, and decrease of -17.87% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Karyopharm Therapeutics Inc. reported EPS of -$3.82, missing estimates by -19.63%, and revenue of $44.04M, 4.78% above expectations.
The stock price moved up 4.66%, changed from $5.80 before the earnings release to $6.07 the day after.
The next earning report is scheduled for Feb 12, 2026.
Based on 8 analysts, Karyopharm Therapeutics Inc. is expected to report EPS of -$2.14 and revenue of $36.17M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement